Introduction of hsa-MiR-512-3p as a New Regulator of HER2 Signaling Pathway in Breast Cancer

Researchers found that miR-512-3p acted as a cell-type-specific tumor suppressor, through targeting HER2, HER3, PIK3R2, and AKT1 transcripts.
[Breast Cancer Research and Treatment]
Mohamadzade, Z., Mahjoubi, F., & Soltani, B. M. (2020). Introduction of hsa-miR-512-3p as a new regulator of HER2 signaling pathway in breast cancer. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-020-05937-3 Cite
Abstract
Bookmark

No account yet? Register

0
Share

MicroRNA-3613-5p Promotes Lung Adenocarcinoma Cell Proliferation through a RELA and AKT/MAPK Positive Feedback Loop

Researchers determined that microRNA-3613-5p plays a crucial role in RELA-mediated post-transcriptional regulation of lung adenocarcinoma cell proliferation.
[Molecular Therapy-Nucleic Acids]
He, T., Shen, H., Wang, S., Wang, Y., He, Z., Zhu, L., Du, X., Wang, D., Li, J., Zhong, S., Huang, W., & Yang, H. (2020). MicroRNA-3613-5p promotes lung adenocarcinoma cell proliferation through a RELA and AKT/MAPK positive feedback loop. Molecular Therapy - Nucleic Acids, 0(0). https://doi.org/10.1016/j.omtn.2020.09.024 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

LncRNA BCYRN1 Inhibits Glioma Tumorigenesis by Competitively Binding with miR-619-5p to Regulate CUEDC2 Expression and the PTEN/AKT/p21 Pathway

Three fresh tumor tissues from glioma patients and three normal brain tissues from craniocerebral trauma patients were prepared for high-throughput RNA sequencing.
[Oncogene]
Mu, M., Niu, W., Zhang, X., Hu, S., & Niu, C. (2020). LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively binding with miR-619-5p to regulate CUEDC2 expression and the PTEN/AKT/p21 pathway. Oncogene, 1–14. https://doi.org/10.1038/s41388-020-01466-x Cite
Full Article
Bookmark

No account yet? Register

0
Share

Brassicasterol from Edible Aquacultural Hippocampus abdominalis Exerts an Anti-Cancer Effect by Dual-Targeting AKT and AR Signaling in Prostate Cancer

Investigators evaluated the effect of seahorse on human prostate cancer using various in vitro methods and identified bioactive compound. Seahorse lipid extract decreased androgen receptor and prostate-specific antigen expression in dihydrotestosterone-induced LNCaP cells of prostate cancer.
[Biomedicines]
Xu, Y., Ryu, S., Lee, Y.-K., & Lee, H.-J. (2020). Brassicasterol from Edible Aquacultural Hippocampus abdominalis Exerts an Anti-Cancer Effect by Dual-Targeting AKT and AR Signaling in Prostate Cancer. Biomedicines, 8(9), 370. https://doi.org/10.3390/biomedicines8090370 Cite
Full Article
Bookmark

No account yet? Register

0
Share

A Novel β2-AR/YB-1/β-Catenin Axis Mediates Chronic Stress-Associated Metastasis in Hepatocellular Carcinoma

Investigators performed immunoprecipitation-mass spectrometry analysis of hepatocellular carcinoma (HCC) tissues. A vital oncoprotein, Y-box binding protein 1 (YB-1), was shown to interact with β2-adrenergic receptor (β2-AR) in HCC cells.
[Oncogenesis]
Full Article
Bookmark

No account yet? Register

0
Share

PI3K/AKT Pathway as a Key Link Modulates the Multidrug Resistance of Cancers

The authors highlight the aberrant activation of PI3K/AKT as a key link that modulates multidrug resistance (MDR). They summarize the regulation of numerous major targets correlated with the PI3K/AKT pathway.
[Cell Death & Disease]
Full Article
Bookmark

No account yet? Register

0
Share

Loss of Proprotein Convertase Furin in Mammary Gland Impairs proIGF1R and proIR Processing and Suppresses Tumorigenesis in Triple Negative Breast Cancer

Investigators report that Furin was frequently overexpressed in TNBC tumors and this correlated with poor prognosis in patients with TNBC tumors.
[Cancers]
He, Z., Khatib, A.-M., & Creemers, J. W. M. (2020). Loss of Proprotein Convertase Furin in Mammary Gland Impairs proIGF1R and proIR Processing and Suppresses Tumorigenesis in Triple Negative Breast Cancer. Cancers, 12(9), 2686. https://doi.org/10.3390/cancers12092686 Cite
Abstract
Bookmark

No account yet? Register

0
Share

A Novel lncRNA LNC_000052 Leads to the Dysfunction of Osteoporotic BMSCs via the miR-96-5p–PIK3R1 Axis

The authors found that both LNC_000052 and PIK3R1 shared a miRNA target, miR-96-5p, which was downregulated in osteoporotic bone-marrow derived MSCs.
[Cell Death & Disease]
Li, M., Cong, R., Yang, L., Yang, L., Zhang, Y., & Fu, Q. (2020). A novel lncRNA LNC_000052 leads to the dysfunction of osteoporotic BMSCs via the miR-96-5p–PIK3R1 axis. Cell Death & Disease, 11(9), 1–13. https://doi.org/10.1038/s41419-020-03006-7 Cite
Full Article
Bookmark

No account yet? Register

0
Share

A20 Promotes Melanoma Progression via the Activation of Akt Pathway

The authors report that A20 played an oncogenic role in melanoma. They first found that the expression of A20 was significantly up-regulated in melanoma cell lines.
[Cell Death & Disease]
Ma, J., Wang, H., Guo, S., Yi, X., Zhao, T., Liu, Y., Shi, Q., Gao, T., Li, C., & Guo, W. (2020). A20 promotes melanoma progression via the activation of Akt pathway. Cell Death & Disease, 11(9), 1–12. https://doi.org/10.1038/s41419-020-03001-y Cite
Full Article
Bookmark

No account yet? Register

0
Share

piR-001773 and piR-017184 Promote Prostate Cancer Progression by Interacting with PCDH9

The downregulation of PCDH9 in pancreatic cells resulted in an increase in AKT phosphorylation and activity. PCDH9 was posttranscriptionally regulated by P-element-induced wimpy-interacting (piR)-001773 and piR-017184.
[Cellular Signalling]
Zhang, L., Meng, X., Li, D., & Han, X. (2020). piR-001773 and piR-017184 promote prostate cancer progression by interacting with PCDH9. Cellular Signalling, 109780. https://doi.org/10.1016/j.cellsig.2020.109780 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

Immunity Pharma Announces Promising Interim Results of its Phase I/IIa Study with IPL344 in ALS

Immunity Pharma, a clinical-stage neurology-focused biopharmaceutical company, announced interim results from its Phase I/IIa clinical study with IPL344, an Akt activating disease-modifying drug for the treatment of ALS. In this early stage clinical trial, disease progression rate during IPL344 treatment was about 50% slower than expected without treatment, in both functional and respiratory endpoints. The drug also demonstrated a very favorable safety and tolerability profile.
[Immunity Pharma Inc.]
Press Release
Bookmark

No account yet? Register

0
Share
Share